Home » Tenders » Americas » USA » Tender 137301615

Department of War Pharmacy Uniform Formulary Et Tender - 137301615

The DEPT OF DEFENSE | DEFENSE HEALTH AGENCY (DHA) has issued a Tender notice for the procurement of a Department of War Pharmacy Uniform Formulary Et Purchase Agreement Uniform Formulary Additional Discount Program in the USA. This Tender notice was published on 07 Mar 2026 and is scheduled to close on 11 Mar 2026, with an estimated Tender value of Refer Document. Interested bidders can access detailed Tender information, eligibility criteria, and complete bidding documents by referencing TOT Ref No. 137301615, while the tender notice number is HT9402-26-Q-9202 and Registering on the platform.

Procurement Summary

Country: USA

Summary: Department of War Pharmacy Uniform Formulary Et Purchase Agreement Uniform Formulary Additional Discount Program

Deadline: 11 Mar 2026

Posting Date: 07 Mar 2026

Other Information

Notice Type: Tender

TOT Ref.No.: 137301615

Document Ref. No.: HT9402-26-Q-9202

Competition: ICB

Financier: Self Financed

Purchaser Ownership: Public

Tender Value: Refer Document

Purchaser's Detail

Name: Login to see tender_details

Address: Login to see tender_details

Email: Login to see tender_details

Tender Details

The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: The following May 2026 drug classes/subclass or newly approved drugs will be reviewed:
a. Cardamyst - Calcium Channel Blocking Agents - NA
b. Myqorzo - Cardiovascular Agents Miscellaneous - NA
c. Ontralfy - Skeletal Muscle Relaxants and Combinations - NA
d. Pivya - Antibiotics - Beta-lactams
e. Sdamlo - Calcium Channel Blocking Agents - NA
f. Vybrique - Phosphodiesterase-5 Inhibitors - Erectile Dysfunction
g. Zycubo - Electrolyte-Mineral-Trace Element Replacement - NA
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9202.
Pre-quotation teleconference is on March 11, 2026. Details are stated in Part 2.4. Pre-Quotation Telecon...
Notice ID: ht9402-26-q-9202

Department/Ind. Agency: dept of defense

Sub-tier: defense health agency (dha)

Office: defense health agency

Product Service Code: 6505 - drugs and biologicals

NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing

Inactive Dates: sep 05, 2026

Inactive Policy: manual

Documents

Browse More

All Tenders From Americas

Procurement Documents for USA

Access a comprehensive library of standard procurement documents specific to USA. Here, you'll find all the essential forms, guidelines, and templates required for tender applications and submissions in USA

Explore Procurement Documents for USA

Want To Bid in This Tender?

Get Local Agent Support in USA and 60 More Countries.

View All The Services

View Tenders By